Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 12, 2010, Pages 1354-1364

  Cameron, C ^a   Van Zanten, S V ^b   Skedgel, C ^c   Flowerdew, G ^a   Moayyedi, P ^d   Sketris, I ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Capital District Health Authority   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; ELDERLY CARE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ULCER;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COST-BENEFIT ANALYSIS; GASTROINTESTINAL DISEASES; HUMANS; PROTECTIVE AGENTS; PROTON PUMP INHIBITORS; STATISTICS AS TOPIC;

EID: 77952779610     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04305.x     Document Type: Article

References (59)

1. Morgan S, McMahon M, Lam J, Mooney D, Raymond C. The Canadian Rx Atlas.
2. Badley E, DesMeules M, editors. Arthritis in Canada : an ongoing challenge. 2005.
3. Cavallucci S. The top 200. What's making waves in prescription sales. Pharm Pract 2006 22 : 44 9.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 343 : 1520 1528.
5. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 364 : 665 674. (Pubitemid 39140622)
6. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 284 : 1247 1255.
7. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 123 : 241 249.
8. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000 27 : 2203 2214.
9. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004 329 : 948.
10. Brown TJ, Hooper L, Elliott RA, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess. 2006 10 : iii iv, xi-xiii, 1-183.
11. Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report. Optimal Therapy Report - COMPUS; 1 (2).
12. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007 369 : 465 473.
13. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000 85 : 169 182.
14. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002 123 : 1006 1012.
15. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000 160 : 2093 2099.
16. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996 28 : 204 210.
17. Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009 29 : 481 496.
18. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001 120 : 594 606.
19. Canadian Agency for Drugs and Technologies in Health. Current Practice Analysis Report for the Prescribing and use of Proton Pump Inhibitors. Optimal Therapy Report - COMPUS 2007 1(5).
20. Nova Scotia Pharmacare. Pharmacists' Bulletin: Nova Scotia Benior's Pharmacare Program 2007 7 (12 1 2.
21. Ontario Drug Benefit Formulary/Comparative Drug Index. Available at: http://www.health.gov.on.ca/english/providers/program/drugs/odbf-eformulary. html.
22. Proton pump inhibitor use in seniors: an analysis focusing on drug claims, 2001 to 2008. 2009.
23. Micklewright R, Lane S, Linley W, McQuade C, Thompson F, Maskrey N. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003 17 : 321 332.
24. Tannenbaum H, Bombardier C, Davis P, Russell AS, Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006 33 : 140 157.
25. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000 162 (12 Suppl S3 23.
26. Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 2007 46 : 265 272. (Pubitemid 46189787)
27. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004 328 : 1415 1416.
28. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 332 : 1302 1308.
29. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 296 : 1633 1644.
30. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a cochrane collaboration systematic review. Clin Gastroenterol Hepatol 2007 5 : 818 828. e5.
31. Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006 119 : 448.e27 36.
32. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002 325 : 624.
33. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004 99 : 1238 1246.
34. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003 49 : 508 518.
35. Ford AC, Forman D, Bailey AG, Cook MB, Axon AT, Moayyedi P. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007 102 : 957 965.
36. Ahlawat SK, Richard Locke G, Weaver AL, Farmer SA, Yawn BP, Talley NJ. Dyspepsia consulters and patterns of management: a population-based study. Aliment Pharmacol Ther 2005 22 : 251 259.
37. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006 26 : 410 420.
38. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005 43 : 736 749.
39. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997 44 : 545 555.
40. Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW, editors. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms.
41. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes.
42. Health Costing in Alberta: 2006 Annual Report.
43. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 2006.
44. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008 179 : 319 326.
45. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005 294 : 2989 2995.
46. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004 292 : 1955 1960.
47. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 1992 146 : 473 481.
48. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004 329 : 224 227.
49. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005 53 : 185 197.
50. Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology (Oxford) 2006 45 : 606 613.
51. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996 334 : 1435 1439.
52. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006 55 : 1731 1738.
53. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 296 : 2947 2953.
54. Brighton B, Bhandari M, Tornetta P III., Felson DT. Hierarchy of evidence: from case reports to randomized controlled trials. Clin Orthop Relat Res 2003 413 : 19 24.
55. Stockl K, Cyprien L, Chang EY. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 2005 11 : 550 558.
56. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007 11 : iii iv, 1-164.
57. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2003 17 : 841 851.
58. Talley NJ, Boyce P, Jones M. Dyspepsia and health care seeking in a community: How important are psychological factors? Dig Dis Sci 1998 43 : 1016 1022.
59. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther 2006 24 : 897 908.